Bexion Pharmaceuticals is a clinical-stage biopharmaceutical company developing an agent composed of the multifunctional, lysosomal activator protein Saposin C and phosphatidylserine. Demonstrating pre-clinical antitumor effects in vitro and in vivo, particularly in brain and other solid tumors, including those that may lead to brain metastases, the firm has completed multi-site first-in-human Phase 1 Parts 1 and 2 clinical studies of the agent for solid tumors and gliomas. A Phase 1 Part 3 expansion phase study is currently enrolling patients. The firm's findings may offer some promise for fighting pancreatic cancer and certain brain tumors â two of the most devastating cancers and among the most difficult to treat. Current cancer treatments often include long rounds of radiation and chemotherapy, surgery and bone-marrow transplants. In animal testing, Bexionâs drug has shown early results of causing cancer cells to destroy themselves while leaving healthy cells unharmed. Based on a compound developed from human proteins and lipids and that is found in human cells, the firm's research on the BXQ-350 nanovesicles has shown the compound killed human brain, nerve, and breast cancer cells in test tubes. Experiments also showed the growth of human brain and nerve cancers transplanted into mice also stopped with no observable adverse effects after 5 weeks of do
